BioVie pauses patient enrollment in BIV201's Phase 2b trial for ascites after positive data; initiates FDA discussions on pivotal Phase 3 trialProactive Investors • 03/13/23
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational TrialGlobeNewsWire • 03/13/23
BioVie's drug NE3107 shown to help patients with muscle control in Parkinson's disease Phase 2 trialProactive Investors • 03/06/23
BioVie Announces Additional Findings from Phase 2 Parkinson's Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placeboGlobeNewsWire • 03/06/23
BioVie shares new insight behind NE3107 molecule development and inhibiting inflammationProactive Investors • 03/02/23
BioVie announces completion of patient enrollment in Phase 3 trial assessing NE3107 in Alzheimer'sProactive Investors • 03/02/23
BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer's DiseaseGlobeNewsWire • 03/02/23
Does BioVie Inc. (BIVI) Have the Potential to Rally 52% as Wall Street Analysts Expect?Zacks Investment Research • 12/27/22
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Cuong Do, President & CEO BioVie Inc.Accesswire • 12/13/22
BioVie updates investors on its Alzheimer's and Parkinson's clinical programsProactive Investors • 12/07/22
BioVie: Treating Alzheimer's, Parkinson's, And Potentially Reversing The Biological ClockSeeking Alpha • 12/06/22
BioVie announces positive results from two Phase 2 trials assessing NE3107's potential in Parkinson's Disease and Alzheimer's DiseaseProactive Investors • 12/06/22
BioVie Announces Additional Findings from Phase 2 Alzheimer's Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in DementiaGlobeNewsWire • 12/06/22